TAS-102 and Anlotinib in ≥3 Lines mGC

Phase 2 Unknown 45 enrolled Zhejiang University

NaSingle-groupOpen-labelTreatment

Summary

To determine the efficacy and safety of TAS-102 and Anlotinib in patients with metastatic gastric cancer who had been treated with ≥ 2 lines of prior standard chemotherapy

Timeline

Start: 2021-09-01
Primary completion: 2024-12-31
Completion: 2024-12-31

Publications

Ying T, Xia R, Zhang Y, Dai J, Wang Y, Xie X. Cost-effectiveness analysis of trifluridine/tipiracil in the treatment of heavily pretreated metastatic gastric cancer from the perspective of Chinese healthcare system. BMJ Open. 2024 Nov 7;14(11):e080846. doi: 10.1136/bmjopen-2023-080846.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	10 mg	Oral
Subject	TAS-102	Small molecule	35 mg/m2	Oral

TAS-102 and Anlotinib in ≥3 Lines mGC

Summary

Timeline

Publications

Drugs

Indications